AML

AML is caused by mutations in genetic coding that is responsible for the formation of cellular blood components. Although unknown, risk factors for these mutations include radiation, chemotherapeutic medications, smoking, aplastic anemia, and genetics. Regardless of the etiology, AML can result in ineffective hematopoiesis and bone marrow failure. Consequently, the body loses the ability to efficiently created specialized cells, but rather producing very little white blood cells or immature white blood cells that lack the functionality required to protect the patient from developing an infection. This leaves the body Immunocompromised, leaving the patient increasingly susceptible to the development of an infection. Albeit widespread, AML can affect multiple systems and organs throughout the body. The underproduction of or production of immature red blood cells results in the development of anemia, which can affect the distribution of oxygen throughout the body and result in manifestations of shortness of breath, air hunger, and tachycardia. The same underproduction or production of immature platelets can result in hemophilia, a condition where the blood is not able to clot properly. This can lead to bleeding and symptoms such as hypotension and ecchymosis. The current goal of treatment involves elimination of the unspecialized, immature cells through chemotherapy or medications. (Ignatavicius et al, 2021) (Vakiti & Mewawalla, 2023).